"If the FDA is reviewing the science, and they find it sufficient to move these peptides onto the category 1 list, this absolutely opens the door to more research and more understanding and more evidence for not only the efficacy but also the safety of the medications. Early peptide adopters will benefit most Not all peptide users are 45-year-old Huberman Lab stans with an unexamined fear of aging
References: Garcia JM, Merriam GR, Kargi AY
Punctum on two different transcription factors regulated by PGC-1alpha: nuclear factor erythroid-derived 2-like 2 and nuclear respiratory factor 2
The specific GLP-1 medications in current use Three GLP-1 receptor agonists dominate the current landscape
It involves understanding local insurance patterns, recognizing when sleep apnea changes eligibility, ordering appropriate testing, and discussing realistic options when coverage is limited
2024 [citato 30 giugno 2024]